The Israel Institute for Biological research

Name

The Israel Institute for Biological research

Legal name

The Israel Institute for Biological Research

Website

https://iibr.gov.il

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biological and Chemical Defense Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Testing Laboratories and Services (541380), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Biological defense research
• Vaccine development services
• Monoclonal antibody therapeutics
• Chemical protection testing
• Environmental hazard detection

Headquarters

HQ city

Ness Ziona

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. Government Funding: IIBR operates as a governmental research institute under the Prime Minister's Office as a statutory unit (established 1952). Primary funding comes from government budget allocations for national defense and security research.
2. LSRI Commercial Services: Life Science Research Israel Ltd. (LSRI) serves as the commercial arm of IIBR, providing validation services, licensing, and collaborative arrangements with external parties.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Israel Institute for Biological Research (IIBR) is a governmental national research institute that develops vaccines, therapeutic antibodies, and advanced detection and protection technologies for biological and chemical defense. Its core activities cover multi-disciplinary biology, chemistry, and environmental sciences research; cGMP biopharmaceutical manufacturing; production of vaccines such as BriLife (COVID-19) and neutralizing monoclonal antibodies; and operation of unique certified laboratories for detection, identification, and physical protection validation. Commercial and licensing activities are executed through its wholly-owned subsidiary LSRI (Life Science Research Israel Ltd.).

Product overview

The Israel Institute for Biological Research (IIBR) is a governmental research institute offering a comprehensive portfolio of biological, chemical, and environmental research services and products. The core offerings include the BriLife COVID-19 vaccine and monoclonal antibody therapeutics, specialized laboratory services for detection/identification of biological and chemical threats, and Physical Protection National Lab testing services. The institute operates unique laboratories for biology (detection/identification), chemistry, and physical protection evaluation. LSRI serves as the commercial arm for technology transfer. Research divisions include Biology (with cGMP biopharmaceutical manufacturing), Chemistry (synthesis, analytical R&D, pharmacology/toxicology), and Environmental Sciences (meteorology, atmospheric modeling, wind tunnel, aerosol research). IIBR provides national lab testing and certification for protective equipment.

Differentiator

Problem solved

Functional benefit

Products and services

• BriLife COVID-19 Vaccine A recombinant VSV-ΔG-spike vaccine candidate developed for protection against SARS-CoV-2. Designed for single-dose administration; demonstrated protective efficacy in animal models and advanced to Phase I/II clinical trials in Israel.
• Monoclonal Antibodies (COVID-19) Neutralizing monoclonal antibodies developed against SARS-CoV-2 for therapeutic use, including the MD65 antibody (100% survival protection in animal models at 3 days post-infection). Patent applications filed for eight such antibodies.
• Unique Laboratory Services (Detection, Identification & Physical Protection) Specialized laboratory services across biology (detection and identification of biological agents), chemistry (detection and identification of chemical agents), and physical protection (evaluation and qualification of protective equipment against chemical warfare agents). Delivered through certified national laboratories.
• Biology Research Services Multi-disciplinary biology research including detection and identification of biological threats, disease and animal models, pathogenesis studies, vaccine development, therapeutic strategies, and cGMP biopharmaceutical manufacturing for national preparedness.
• Chemistry Research Services Comprehensive chemistry capabilities including organic/inorganic synthesis, analytical R&D (GC/MS and LC/MS), pharmacology and toxicology, active molecule design and testing, and environmental toxic pollutant research.
• Environmental Sciences Research Services Environmental research including meteorological measurements, atmospheric transport modeling, the Environmental Wind Tunnel Laboratory, aerosol research, risk assessment, and detection and identification of hazardous materials.
• Physical Protection National Laboratory Tests National R&D laboratory testing services for evaluation and validation of personal respiratory filters, shelter and vehicle filters, gas masks, protective hoods, and protective clothing against toxic industrial chemicals, environmental pollutants, and chemical warfare agents.
• Stand-off Detection Systems Remote sensing systems for detection of hazardous substances, including laser-induced fluorescence (LIF) standoff biological detection, hyperspectral imaging from VIS to LWIR, and QCL-based LIDAR systems for gas detection.
• Dermal Protection Evaluation Services Evaluation services for protection efficacy of protective gear against transdermal poisoning, including studies of chemical agent transport through barriers, aging mechanisms, and self-decontamination treatments.
• Respiratory Protection Evaluation Services Evaluation of protection efficacy of personal filters, collective-protection filters, and gas masks against chemical warfare agents and toxic industrial contaminants using controlled-atmosphere aerosol exposure chamber testing.
• LAMP-Seq Molecular Barcode Testing Technology Pooled testing technology enabling sensitive and complex COVID-19 diagnosis with molecular barcode-based identification of individual samples within pooled reactions (100% sensitivity / 99.7% specificity at Ct≤33).
• LSRI (Life Science Research Israel Ltd.) Commercial Arm Services Governmental commercial arm providing validation services, licensing, and collaborative R&D/co-development arrangements to external parties domestically and internationally.

Quantifiable outcome

• Single dose of BriLife vaccine provides complete protection against SARS-CoV-2 challenge in animal models
• +4 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature13 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Dyadic International, Inc.coreStrategic or Co-development Partner · 1 January 2020Collaboration to explore the potential of Dyadic's C1 gene expression platform for expressing IIBR-developed gene sequences into recombinant vaccine candidates and monoclonal antibodies to combat emerging diseases and threats including COVID-19.
• Weizmann Institute of SciencecoreStrategic or Co-development Partner · 1 January 2020MoU signed for collaboration on coronavirus research including joint development of rapid detection systems, antibody characterization, and genomic studies of SARS-CoV-2 proteins.
• Hadassah Medical Center Ein KaremminorStrategic or Co-development Partner · 1 January 2020Joint development of antibacterial and antiviral spray coating for single-use masks demonstrating strong and rapid activity lasting at least 6 months.
• Terra NobleminorStrategic or Co-development Partner · 1 January 2020Collaboration partner in development of antiviral spray coating technology for protective masks.
• Sirbright (Aposense subsidiary)minorStrategic or Co-development Partner · 1 January 2020Joint research collaboration for accelerated development of COVID-19 treatment based on siRNA molecular motor technology platform for genetic therapy against viral respiratory diseases.
• Shaarey Zedek Medical CenterminorStrategic or Co-development Partner · 1 January 2020First-of-its-kind collaboration to explore new method for detecting coronavirus markers through breath analysis using IIBR's unique volatile compound analysis capabilities.
• ESIL Innovation LabminorStrategic or Co-development Partner · 1 January 2020Partnership for development of advanced environmental technologies for early detection of pollutants; sharing information on startups and R&D solutions relevant to both organizations.
• TLS and AOUCminorStrategic or Co-development Partner · 1 January 2020MoU signed to examine conditions for developing project to isolate new antibodies targeting neutralization of the coronavirus.
• Assuta Ashdod HospitalminorStrategic or Co-development Partner · 1 January 2020Joint study with IIBR researchers on viability of coronavirus on surfaces in patient environments.
• Laniado HospitalminorStrategic or Co-development Partner · 1 January 2020Joint study with IIBR researchers on viability of coronavirus on surfaces in patient environments.
• Dyadic International, Inc. (Initial Collaboration)coreStrategic or Co-development Partner · 1 January 2018Original R&D collaboration to advance C1 expression platform for development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Swedish Defence Research Agency (FOI): Swedish governmental defense research institute covering CBRN defense, life sciences, and environmental security. Direct peer to IIBR with comparable multi-disciplinary scope including chemistry, biology, and environmental/atmospheric research.
• Institut de Recherche Biomédicale des Armées (IRBA): French military biomedical research institute conducting infectious disease research, vaccine development, and CBRN defense. Direct peer in mission, organizational structure, and research portfolio, including clinical research and pharmaceutical development.
• Emergent BioSolutions: U.S. specialty biopharmaceutical company focused on biodefense products including vaccines (anthrax, smallpox) and antibody therapeutics. Direct peer in biodefense vaccine/antibody commercialization, CBRN countermeasures, and government contracting.
• USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases): The U.S. Army's primary laboratory for defensive medical research against biological threats, conducting infectious disease research, vaccine development, and diagnostics. Direct counterpart to IIBR in mission scope, operating model, and product portfolio (vaccines, antibodies, detection).
• Bavarian Nordic: Danish biotech company specializing in orthopoxvirus (smallpox, monkeypox) and infectious disease vaccines. Closely comparable to IIBR's orthopoxvirus mAb work and vaccine platform IP, with commercial-scale GMP manufacturing.
• Defence Science and Technology Laboratory (Dstl): UK's leading governmental defense science organization, providing CBRN defense, life sciences, and chemical/biological threat research. Directly comparable to IIBR as a state-owned defense science lab with multi-disciplinary biology, chemistry, and environmental capabilities.
• SIGA Technologies: U.S. biodefense pharmaceutical company developing and commercializing smallpox antiviral treatments (TPOXX) and orthopoxvirus countermeasures. Comparable to IIBR's CBRN therapeutic IP and government biodefense contracting model.
• Bundeswehr Institute of Microbiology: German military medical institute focused on infectious disease diagnostics, vaccine development, and biodefense research. Closely aligned with IIBR's biology division in scope, mission (military biodefense), and product orientation (vaccines, antibodies, detection).

Emerging players

• Robert Koch Institute: Germany's federal public health and infectious disease research institute. Comparable to IIBR's disease detection/identification and pandemic preparedness work, though broader in public health scope and less focused on defense/CBRN applications.

Broad incumbents

• BARDA (Biomedical Advanced Research and Development Authority): U.S. federal authority funding advanced development of medical countermeasures (vaccines, therapeutics, diagnostics) against CBRN and pandemic threats. Adjacent to IIBR as a major biodefense counterpart, though functioning primarily as a funder/contractor rather than a research lab.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/israel-institute-for-biological-research-iibr

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Israel Institute for Biological research